blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3455203

EP3455203 - VINYLOGOUS PHENETHYLAMINES AS NEUROTRANSMITTER RELEASERS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  29.07.2022
Database last updated on 03.10.2024
FormerThe patent has been granted
Status updated on  20.08.2021
FormerGrant of patent is intended
Status updated on  10.05.2021
FormerExamination is in progress
Status updated on  19.06.2020
FormerRequest for examination was made
Status updated on  15.02.2019
FormerThe international publication has been made
Status updated on  17.11.2017
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024 [2024/42]
Applicant(s)For all designated states
Research Triangle Institute
3040 East Cornwallis Road
Research Triangle Park, NC 27709 / US
[2021/38]
Former [2021/23]For all designated states
Research Triangle Institute
3040 Cornwallis Road
Research Triangle Park, NC 27709 / US
Former [2019/12]For all designated states
Research Triangle Institute
3040 Cornwallis Road
P.O. Box 12194
Research Triangle Park, North Carolina 27709 / US
Inventor(s)01 / BLOUGH, Bruce
3417 Trinity Farms Road
Raleigh, NC 27607 / US
02 / DECKER, Ann
5910 Forest Ridge Drive
Durham, NC 27713 / US
03 / ROTHMAN, Richard
12719 Folly Quarter Rd.
Ellicott City, MD 21042 / US
 [2019/12]
Representative(s)Murgitroyd & Company
165-169 Scotland Street
Glasgow G5 8PL / GB
[N/P]
Former [2021/38]Murgitroyd & Company
Murgitroyd House
165-169 Scotland Street
Glasgow G5 8PL / GB
Former [2019/12]Murgitroyd & Company
Scotland House
165-169 Scotland Street
Glasgow G5 8PL / GB
Application number, filing date17796833.611.05.2017
[2019/12]
WO2017US32143
Priority number, dateUS201662335191P12.05.2016         Original published format: US 201662335191 P
[2019/12]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2017197101
Date:16.11.2017
Language:EN
[2017/46]
Type: A1 Application with search report 
No.:EP3455203
Date:20.03.2019
Language:EN
The application published by WIPO in one of the EPO official languages on 16.11.2017 takes the place of the publication of the European patent application.
[2019/12]
Type: B1 Patent specification 
No.:EP3455203
Date:22.09.2021
Language:EN
[2021/38]
Search report(s)International search report - published on:KR16.11.2017
(Supplementary) European search report - dispatched on:EP14.10.2019
ClassificationIPC:C07C211/28, A61K31/135, A61K31/137, A61P25/30
[2021/20]
CPC:
C07C211/28 (EP,US); A61K31/135 (US); A61P25/30 (EP,US);
C07B2200/07 (EP,US)
Former IPC [2019/12]C07C211/28, A61K31/135, A61K31/137
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/12]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
MDNot yet paid
TitleGerman:VINYLOGE PHENETHYLAMINE ALS NEUROTRANSMITTERFREISETZER[2019/12]
English:VINYLOGOUS PHENETHYLAMINES AS NEUROTRANSMITTER RELEASERS[2019/12]
French:PHÉNÉTHYLAMINES VINYLOGUES À TITRE DE LIBÉRATEURS DE NEUROTRANSMETTEURS[2019/12]
Entry into regional phase23.10.2018National basic fee paid 
23.10.2018Search fee paid 
23.10.2018Designation fee(s) paid 
23.10.2018Examination fee paid 
Examination proceduredeletedDate on which the examining division has become responsible
23.10.2018Examination requested  [2019/12]
14.01.2020Amendment by applicant (claims and/or description)
23.06.2020Despatch of a communication from the examining division (Time limit: M04)
20.10.2020Reply to a communication from the examining division
11.05.2021Communication of intention to grant the patent
16.08.2021Fee for grant paid
16.08.2021Fee for publishing/printing paid
16.08.2021Receipt of the translation of the claim(s)
Opposition(s)23.06.2022No opposition filed within time limit [2022/35]
Fees paidRenewal fee
30.05.2019Renewal fee patent year 03
30.03.2020Renewal fee patent year 04
21.05.2021Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU11.05.2017
AL22.09.2021
AT22.09.2021
CY22.09.2021
CZ22.09.2021
DK22.09.2021
EE22.09.2021
FI22.09.2021
HR22.09.2021
LT22.09.2021
LV22.09.2021
MC22.09.2021
MK22.09.2021
MT22.09.2021
NL22.09.2021
PL22.09.2021
RO22.09.2021
RS22.09.2021
SE22.09.2021
SI22.09.2021
SK22.09.2021
SM22.09.2021
TR22.09.2021
BG22.12.2021
NO22.12.2021
GR23.12.2021
IS22.01.2022
PT24.01.2022
IE11.05.2022
LU11.05.2022
BE31.05.2022
CH31.05.2022
LI31.05.2022
[2024/42]
Former [2024/29]HU11.05.2017
AL22.09.2021
AT22.09.2021
CY22.09.2021
CZ22.09.2021
DK22.09.2021
EE22.09.2021
FI22.09.2021
HR22.09.2021
LT22.09.2021
LV22.09.2021
MC22.09.2021
MK22.09.2021
NL22.09.2021
PL22.09.2021
RO22.09.2021
RS22.09.2021
SE22.09.2021
SI22.09.2021
SK22.09.2021
SM22.09.2021
TR22.09.2021
BG22.12.2021
NO22.12.2021
GR23.12.2021
IS22.01.2022
PT24.01.2022
IE11.05.2022
LU11.05.2022
BE31.05.2022
CH31.05.2022
LI31.05.2022
Former [2024/23]HU11.05.2017
AL22.09.2021
AT22.09.2021
CY22.09.2021
CZ22.09.2021
DK22.09.2021
EE22.09.2021
FI22.09.2021
HR22.09.2021
LT22.09.2021
LV22.09.2021
MC22.09.2021
MK22.09.2021
NL22.09.2021
PL22.09.2021
RO22.09.2021
RS22.09.2021
SE22.09.2021
SI22.09.2021
SK22.09.2021
SM22.09.2021
BG22.12.2021
NO22.12.2021
GR23.12.2021
IS22.01.2022
PT24.01.2022
IE11.05.2022
LU11.05.2022
BE31.05.2022
CH31.05.2022
LI31.05.2022
Former [2024/21]HU11.05.2017
AL22.09.2021
AT22.09.2021
CY22.09.2021
CZ22.09.2021
DK22.09.2021
EE22.09.2021
FI22.09.2021
HR22.09.2021
LT22.09.2021
LV22.09.2021
MC22.09.2021
NL22.09.2021
PL22.09.2021
RO22.09.2021
RS22.09.2021
SE22.09.2021
SI22.09.2021
SK22.09.2021
SM22.09.2021
BG22.12.2021
NO22.12.2021
GR23.12.2021
IS22.01.2022
PT24.01.2022
IE11.05.2022
LU11.05.2022
BE31.05.2022
CH31.05.2022
LI31.05.2022
Former [2024/20]HU11.05.2017
AL22.09.2021
AT22.09.2021
CY22.09.2021
CZ22.09.2021
DK22.09.2021
EE22.09.2021
FI22.09.2021
HR22.09.2021
LT22.09.2021
LV22.09.2021
MC22.09.2021
NL22.09.2021
PL22.09.2021
RO22.09.2021
RS22.09.2021
SE22.09.2021
SI22.09.2021
SK22.09.2021
BG22.12.2021
NO22.12.2021
GR23.12.2021
IS22.01.2022
PT24.01.2022
IE11.05.2022
LU11.05.2022
BE31.05.2022
CH31.05.2022
LI31.05.2022
Former [2024/18]HU11.05.2017
AL22.09.2021
AT22.09.2021
CZ22.09.2021
DK22.09.2021
EE22.09.2021
FI22.09.2021
HR22.09.2021
LT22.09.2021
LV22.09.2021
MC22.09.2021
NL22.09.2021
PL22.09.2021
RO22.09.2021
RS22.09.2021
SE22.09.2021
SI22.09.2021
SK22.09.2021
BG22.12.2021
NO22.12.2021
GR23.12.2021
IS22.01.2022
PT24.01.2022
IE11.05.2022
LU11.05.2022
BE31.05.2022
CH31.05.2022
LI31.05.2022
Former [2023/25]AL22.09.2021
AT22.09.2021
CZ22.09.2021
DK22.09.2021
EE22.09.2021
FI22.09.2021
HR22.09.2021
LT22.09.2021
LV22.09.2021
MC22.09.2021
NL22.09.2021
PL22.09.2021
RO22.09.2021
RS22.09.2021
SE22.09.2021
SI22.09.2021
SK22.09.2021
BG22.12.2021
NO22.12.2021
GR23.12.2021
IS22.01.2022
PT24.01.2022
IE11.05.2022
LU11.05.2022
BE31.05.2022
CH31.05.2022
LI31.05.2022
Former [2023/20]AL22.09.2021
AT22.09.2021
CZ22.09.2021
DK22.09.2021
EE22.09.2021
FI22.09.2021
HR22.09.2021
LT22.09.2021
LV22.09.2021
MC22.09.2021
NL22.09.2021
PL22.09.2021
RO22.09.2021
RS22.09.2021
SE22.09.2021
SI22.09.2021
SK22.09.2021
BG22.12.2021
NO22.12.2021
GR23.12.2021
IS22.01.2022
PT24.01.2022
IE11.05.2022
LU11.05.2022
CH31.05.2022
LI31.05.2022
Former [2023/09]AL22.09.2021
AT22.09.2021
CZ22.09.2021
DK22.09.2021
EE22.09.2021
FI22.09.2021
HR22.09.2021
LT22.09.2021
LV22.09.2021
MC22.09.2021
NL22.09.2021
PL22.09.2021
RO22.09.2021
RS22.09.2021
SE22.09.2021
SI22.09.2021
SK22.09.2021
BG22.12.2021
NO22.12.2021
GR23.12.2021
IS22.01.2022
PT24.01.2022
LU11.05.2022
CH31.05.2022
LI31.05.2022
Former [2023/08]AL22.09.2021
AT22.09.2021
CZ22.09.2021
DK22.09.2021
EE22.09.2021
FI22.09.2021
HR22.09.2021
LT22.09.2021
LV22.09.2021
MC22.09.2021
NL22.09.2021
PL22.09.2021
RO22.09.2021
RS22.09.2021
SE22.09.2021
SI22.09.2021
SK22.09.2021
BG22.12.2021
NO22.12.2021
GR23.12.2021
IS22.01.2022
PT24.01.2022
LU11.05.2022
Former [2023/06]AL22.09.2021
AT22.09.2021
CZ22.09.2021
DK22.09.2021
EE22.09.2021
FI22.09.2021
HR22.09.2021
LT22.09.2021
LV22.09.2021
MC22.09.2021
NL22.09.2021
PL22.09.2021
RO22.09.2021
RS22.09.2021
SE22.09.2021
SI22.09.2021
SK22.09.2021
BG22.12.2021
NO22.12.2021
GR23.12.2021
IS22.01.2022
PT24.01.2022
Former [2023/01]AL22.09.2021
AT22.09.2021
CZ22.09.2021
DK22.09.2021
EE22.09.2021
FI22.09.2021
HR22.09.2021
LT22.09.2021
LV22.09.2021
NL22.09.2021
PL22.09.2021
RO22.09.2021
RS22.09.2021
SE22.09.2021
SI22.09.2021
SK22.09.2021
BG22.12.2021
NO22.12.2021
GR23.12.2021
IS22.01.2022
PT24.01.2022
Former [2022/36]AL22.09.2021
AT22.09.2021
CZ22.09.2021
DK22.09.2021
EE22.09.2021
FI22.09.2021
HR22.09.2021
LT22.09.2021
LV22.09.2021
NL22.09.2021
PL22.09.2021
RO22.09.2021
RS22.09.2021
SE22.09.2021
SK22.09.2021
BG22.12.2021
NO22.12.2021
GR23.12.2021
IS22.01.2022
PT24.01.2022
Former [2022/29]AL22.09.2021
AT22.09.2021
CZ22.09.2021
EE22.09.2021
FI22.09.2021
HR22.09.2021
LT22.09.2021
LV22.09.2021
NL22.09.2021
PL22.09.2021
RO22.09.2021
RS22.09.2021
SE22.09.2021
SK22.09.2021
BG22.12.2021
NO22.12.2021
GR23.12.2021
IS22.01.2022
PT24.01.2022
Former [2022/24]AT22.09.2021
CZ22.09.2021
EE22.09.2021
FI22.09.2021
HR22.09.2021
LT22.09.2021
LV22.09.2021
NL22.09.2021
PL22.09.2021
RO22.09.2021
RS22.09.2021
SE22.09.2021
SK22.09.2021
BG22.12.2021
NO22.12.2021
GR23.12.2021
IS22.01.2022
PT24.01.2022
Former [2022/23]AT22.09.2021
CZ22.09.2021
EE22.09.2021
FI22.09.2021
HR22.09.2021
LT22.09.2021
LV22.09.2021
PL22.09.2021
RS22.09.2021
SE22.09.2021
SK22.09.2021
BG22.12.2021
NO22.12.2021
GR23.12.2021
PT24.01.2022
Former [2022/21]AT22.09.2021
FI22.09.2021
HR22.09.2021
LT22.09.2021
LV22.09.2021
RS22.09.2021
SE22.09.2021
BG22.12.2021
NO22.12.2021
GR23.12.2021
Former [2022/10]FI22.09.2021
HR22.09.2021
LT22.09.2021
LV22.09.2021
RS22.09.2021
SE22.09.2021
BG22.12.2021
NO22.12.2021
GR23.12.2021
Former [2022/09]FI22.09.2021
LT22.09.2021
RS22.09.2021
SE22.09.2021
BG22.12.2021
NO22.12.2021
Former [2022/08]FI22.09.2021
LT22.09.2021
SE22.09.2021
BG22.12.2021
NO22.12.2021
Former [2022/07]LT22.09.2021
NO22.12.2021
Documents cited:Search[X]EP0706994  (BRISTOL MYERS SQUIBB CO [US]) [X] 1-4 * page 10, line 35 *;
 [X]WO9833765  (DU PONT [US], et al) [X] 1-4 * page 29, line 14 *;
 [X]WO0023418  (REYNOLDS TOBACCO CO R [US], et al) [X] 1-4 * page 44, line 4 *;
 [X]US6337351  (DULL GARY MAURICE [US], et al) [X] 1-4 * column 29, line 21 * * column 30, line 56 * * column 33, line 29 * * column 35, lines 51-52 * * column 37, line 46 * * column 38, lines 45-46 * * column 39, line 55 * * column 40, lines 64-65 * * column 41, lines 58-59 *;
 [X]WO2004071445  (PHARMACOPEIA DRUG DISCOVERY [US], et al) [X] 1-4,7,8 * page 21, paragraph 54 * * page 22, paragraph 57 * * page 24 * * page 27, lines 1, 5 * * page 28, paragraph 64 *;
 [X]US2006069261  (BONNEAU PIERRE [CA], et al) [X] 1,7,8 * page 24; compound 9.2 *;
 [X]WO2006044823  (AMGEN INC [US], et al) [X] 1,7,8 * page 172; example 166 *;
 [X]WO2008009613  (HOFFMANN LA ROCHE [CH], et al) [X] 1,7-9 * page 45; compounds 88a,b,c * * page 46; compound 92 *;
 [X]US2010168094  (BINCH HAYLEY [US], et al) [X] 1,7,8 * page 61, paragraph 522 - page 62, paragraph 526 *;
 [A]WO2010121022  (RES TRIANGLE INST [US], et al) [A] 1-14 * the whole document *;
 [X]EP2281801  (RAGACTIVES S L U [ES]) [X] 1-4 * page 15, paragraph 80 *;
 [X]WO2011103189  (UWM RES FOUNDATION INC [US], et al) [X] 1-4,9 * page 111, line 8 - page 112, line 1; claim 32 * * claim 57 * * page 102; compound 119 *;
 [X]WO2013048982  (BRISTOL MYERS SQUIBB CO [US]) [X] 1-3 * page 74, line 25 - page 75 *;
 [X]US2014171447  (JOHNSON MICHAEL R [US]) [X] 1,7,8 * page 103; compound 176 * * page 104; compound 177 *;
 [X]  - SALVANT, JUSTIN M. ET AL, "Regioselective Base-Mediated Cyclizations of Mono-N-acylpropargylguanidines", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 2017:885550, URL: STN, XP002794443 [X] 1,7,8 * abstract *
 [P]  - SALVANT, JUSTIN M. ET AL, "Regioselective Base-Mediated Cyclizations of Mono-N-acylpropargylguanidines", JOURNAL OF ORGANIC CHEMISTRY , 82(13), 6958-6967 CODEN: JOCEAH; ISSN: 0022-3263, (2017), doi:10.1021/ACS.JOC.7B00639 10.1021/ACS.JOC.7B00639
 [X]  - YU, ZHIYI ET AL, "Structure-Affinity Relationships (SARs) and Structure-Kinetics Relationships (SKRs) of Kv11.1 Blockers", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 2015:1100250, URL: STN, XP002794444 [X] 1,7,8 * abstract *
    [ ] - YU, ZHIYI ET AL, "Structure-Affinity Relationships (SARs) and Structure-Kinetics Relationships (SKRs) of Kv11.1 Blockers", JOURNAL OF MEDICINAL CHEMISTRY , 58(15), 5916-5929 CODEN: JMCMAR; ISSN: 0022-2623, (2015), doi:10.1021/ACS.JMEDCHEM.5B00518 10.1021/ACS.JMEDCHEM.5B00518
 [X]  - DUFFEY, MATTHEW O. ET AL, "Discovery of a Potent and Orally Bioavailable Benzolactam-Derived Inhibitor of Polo-Like Kinase 1 (MLN0905)", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 2011:1443586, URL: STN, XP002794445 [X] 1,7,8 * abstract *
    [ ] - DUFFEY, MATTHEW O. ET AL, "Discovery of a Potent and Orally Bioavailable Benzolactam-Derived Inhibitor of Polo-Like Kinase 1 (MLN0905)", JOURNAL OF MEDICINAL CHEMISTRY , 55(1), 197-208 CODEN: JMCMAR; ISSN: 0022-2623, (2012), doi:10.1021/JM2011172 10.1021/JM2011172
 [X]  - KWATRA, MADAN M. ET AL, "Acetylenics. 2. Synthesis and pharmacology of certain N,N-dialkyl-3-phenylpropyn-2-amines and some analogs with tryptamine-like behavioral effects in mice", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 1978:83447, URL: STN, XP002794446 [X] 1,7,8 * abstract *
    [ ] - KWATRA, MADAN M. ET AL, "Acetylenics. 2. Synthesis and pharmacology of certain N,N-dialkyl-3-phenylpropyn-2-amines and some analogs with tryptamine-like behavioral effects in mice", JOURNAL OF MEDICINAL CHEMISTRY , 21(3), 253-7 CODEN: JMCMAR; ISSN: 0022-2623, (1978), doi:10.1021/JM00201A003 10.1021/JM00201A003
 [X]  - RODRIGUES, NUNO ET AL, "Synthesis and structure-activity relationship study of substituted caffeate esters as antinociceptive agents modulating the TREK-1 channel", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 2014:367344, URL: STN, XP002794447 [X] 1-4 * abstract *
    [ ] - RODRIGUES, NUNO ET AL, "Synthesis and structure-activity relationship study of substituted caffeate esters as antinociceptive agents modulating the TREK-1 channel", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , 75, 391-402 CODEN: EJMCA5; ISSN: 0223-5234, (2014), doi:10.1016/J.EJMECH.2014.01.049 10.1016/J.EJMECH.2014.01.049
 [X]  - DEWAL, MAHENDER B. ET AL, "Thieno[2,3-d]pyrimidinedione derivatives as antibacterial agents", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 2012:630616, URL: STN, XP002794448 [X] 1-4 * abstract *
    [ ] - DEWAL, MAHENDER B. ET AL, "Thieno[2,3-d]pyrimidinedione derivatives as antibacterial agents", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , 51, 145-153 CODEN: EJMCA5; ISSN: 0223-5234, (2012), doi:10.1016/J.EJMECH.2012.02.035 10.1016/J.EJMECH.2012.02.035
 [X]  - REN, YONG ET AL, "Synthesis and antiarrhythmic activity of (erythro)-phenylpropanediolamine compounds", CA, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, Database accession no. 1997:803082, URL: STN, XP002794449 [X] 1-4 * abstract *
 [XP]  - ANN M. DECKER ET AL, "The biogenic amine transporter activity of vinylogous amphetamine analogs", MEDCHEMCOMM, United Kingdom, (20160630), vol. 7, no. 8, doi:10.1039/C6MD00245E, ISSN 2040-2503, pages 1657 - 1663, XP055624366 [XP] 1-14 * the whole document *

DOI:   http://dx.doi.org/10.1039/C6MD00245E
 [XP]  - JIE LIU ET AL, "Catalytic Asymmetric Umpolung Allylation of Imines", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, US, (20160928), vol. 138, no. 40, doi:10.1021/jacs.6b05288, ISSN 0002-7863, pages 13103 - 13106, XP055626672 [XP] 1-6 * page 13105; table 2; compound 17 *

DOI:   http://dx.doi.org/10.1021/jacs.6b05288
International search[X]US2013296271  (SAKAI MASAAKI [JP], et al) [X] 1, 7-8 * See paragraph [0169]. *;
 [X]US2014336216  (DVORAK CURT A [US], et al) [X] 1-12 * See claim 7; paragraphs [0019], [0028]. *;
 [X]  - Chemical Abstract Compoun, (19870418), Database accession no. 107638-85-7, URL: STN, XP055445233 [X] 1-4 * See the whole document. *
 [X]  - PARPART, S. et al., "Synthes is of optically pure (S)-2-amino-5-arylpent- 4-ynoic acids by Sonogashira reactions and their potential use as highly selective potent inhibitors of aldose reductase", RSC Advances, (20150000), vol. 5, pages 107400 - 107412, XP055439637 [X] 1, 7-8 * See scheme 5. *

DOI:   http://dx.doi.org/10.1039/C5RA22407A
 [A]  - KALIX, P. et al., "Differential effect of phenylpropyl- and phenylpentenyl-khatamines on the release of radioactivity from rabbit atria prelabelled with 3H-noradrenaline", Pharmaceutica acta Helvetiae, (19870000), vol. 62, no. 12, pages 332 - 334, XP009514578 [A] 1-12 * See the whole document. *
by applicantWO2010121022
    - KALIX, P. et al., "Differential effect of phenylpropyl- and phenylpentenyl-khatamines on the release of radioactivity from rabbit atria prelabelled with 3H-noradrenaline", Pharmaceutica acta Helvetiae, (19870000), vol. 62, no. 12, pages 332 - 334, XP009514578
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.